Premium
Development of a Platinum Complex as an anti‐Amyloid Agent for the Therapy of Alzheimer’s Disease
Author(s) -
Kenche Vijaya B.,
Hung Lin W.,
Perez Keyla,
Volitakes Irene,
Ciccotosto Guiseppe,
Kwok Jeffrey,
Critch Nicole,
Sherratt Nikki,
Cortes Mikhalina,
Lal Varsha,
Masters Colin L.,
Murakami Kazuma,
Cappai Roberto,
Adlard Paul A.,
Barnham Kevin J.
Publication year - 2013
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201209885
Subject(s) - amyloid (mycology) , disease , amyloid β , transgene , genetically modified mouse , β amyloid , alzheimer's disease , platinum , p3 peptide , medicine , neuroscience , amyloid precursor protein , pathology , psychology , chemistry , biochemistry , gene , catalysis
Brainwash! A platinum complex (see scheme) was developed that could be administered orally and reduce the amyloid burden in the brains of transgenic mouse models suffering from Alzheimer's disease. Analyses of brain tissues showed that treatment with the Pt compound led to a 26 % decrease in the number of amyloid β‐peptide plaques.